Qiagen NV
NYSE:QGEN
Operating Margin
Qiagen NV
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| NL |
|
Qiagen NV
NYSE:QGEN
|
10.1B USD |
25%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
15%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
150.2B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
140.5B USD |
22%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
32%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.1B CHF |
18%
|
|
| JP |
D
|
DNA Chip Research Inc
TSE:2397
|
6.8T JPY |
4%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.8B USD |
23%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD |
15%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
188.5B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24B USD |
29%
|
Qiagen NV
Glance View
Qiagen NV, a luminary in the realm of biotechnology, navigates the intricate world of molecular diagnostics and testing with a blend of innovation and expertise. Originating in 1984 in the Netherlands, this company has grown into a formidable presence in the life sciences sector. Qiagen's journey revolves around its core mission: to enable advancements in science and healthcare by providing technologies and solutions that unlock molecular insights. At the heart of its operations lies a comprehensive portfolio of sample and assay technologies. These are critical tools for laboratories worldwide, instrumental in the isolation and preparation of nucleic acids, such as DNA and RNA. With these tools, researchers and clinicians can delve deeper into the molecular underpinnings of diseases, paving the way for breakthroughs in diagnostics and treatment. Qiagen’s financial engine is fueled by its diverse array of products and services, ranging from consumables like reagents and kits to sophisticated equipment for automating laboratory processes. Its diagnostic solutions are pivotal in areas like oncology, infectious diseases, and personalized medicine, enabling institutions to detect and analyze genetic information with precision. Additionally, Qiagen earns revenue by supporting pharmaceutical and biotech firms in their quest to discover and develop new drugs, ultimately contributing to safer, more effective treatments. The company also benefits from strategic collaborations and partnerships, continually expanding its influence and technological prowess. Through this multifaceted approach, Qiagen not only thrives in the competitive biotech landscape but also plays a critical role in transforming molecular data into actionable healthcare outcomes.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Qiagen NV's most recent financial statements, the company has Operating Margin of 25%.
You don't have any saved screeners yet